Penetrating pharmaceutical foam
AssigneeFoamix Ltd.
InventorsDov Tamarkin, Doron Friedman, Meir Eini
Life of this patent
Estimating the term…
Abstract
The invention relates to an alcohol-free cosmetic or pharmaceutical foam composition comprising water, a hydrophobic solvent, a surface-active agent, a gelling agent, an active component selected from the group of urea, hydroxy acid and a therapeutic enhancer and a propellant. The foam further comprises active agents and excipients with therapeutic properties having enhanced skin penetration.
Claims28
A foamable composition comprising a carrier and a liquefied or a compressed gas propellant, the carrier comprising:
- i) about 0.1% to about 5% by weight of the carrier of a surface-active agent;
- ii) about 2% to about 75% by weight of the carrier of a liquid, non-volatile hydrophobic solvent;
- iii) about 0.01% to about 5% by weight of the carrier of a gelling agent;
- and
- iv) water,
- wherein the surface active agent is selected from the group consisting of polysorbate, a polyoxyethylene fatty acid ester, a polyoxyethylene alkyl ether, a sucrose ester, a partial ester of sorbitol, a partial ester of sorbitol anhydride, sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, sodium lauryl sulfate, triethanolamine lauryl sulfate, a betaine, a mono-, di- or tri-ester of sucrose with food fatty acids (sucrose esters), a monoglyceride, a diglyceride, polyoxyethylene (20) sorbitan monostearate, polyoxyethylene (20) sorbitan monooleate, Myrj 45 (Polyoxyethylene (8) Stearate), Myrj 49 (polyoxyethylene (20) stearate), Myrj 59 (polyoxyethylene (100) stearate), a polyoxyethylene cetyl ether, a polyoxyethylene palmityl ether, a polyethylene oxide hexadecyl ether, Brij 52 (polyoxyethylene (2) cetyl ether), Brij 56 (polyoxyethylene (10) cetyl ether), sorbitan monolaurate, isoceteth-20, cocamidopropyl betaine, and Myrj 52 (polyoxyethylene 40 stearate);
- wherein a breakable foam forms upon dispensing the foamable composition.
A foamable composition comprising a carrier and a liquefied or a compressed gas propellant, the carrier comprising:
- i) about 0.1% to about 5% by weight of the carrier of a surface-active agent;
- ii) 0.01% to about 5% by weight of the carrier of a gelling agent;
- iii) a therapeutic enhancer selected from the group consisting of a polyhydric alcohol, propylene glycol, butylene glycol, glycerol, pentaerythritol, sorbitol, mannitol, an oligosaccharide, dimethyl isosorbide, monooleate of ethoxylated glycerides (with 8 to 10 ethylene oxide units), a polyethylene glycol 200-600, transcutol (diethylene glycol monoethyl ether), glycofurol (tetrahydrofurfuryl alcohol PEG ether), a cyclodextrin, and mixtures of any two or more thereof;
- and
- iv) water,
- wherein a breakable foam forms upon dispensing the foamable composition.
A foamable composition comprising a carrier and a liquefied or a compressed gas propellant, the carrier comprising:
- i) about 0.1% to about 5% by weight of the carrier of a surface-active agent;
- ii) about 2% to about 75% by weight of the carrier of a liquid, non-volatile hydrophobic solvent;
- iii) about 0.01% to about 5% by weight of the carrier of a gelling agent;
- iv) a foam adjuvant;
- and
- iv) water,
- wherein a breakable foam forms upon dispensing the foamable composition.
A foamable composition comprising a carrier and a liquefied or a compressed gas propellant, the carrier comprising:
- i) about 0.1% to about 5% by weight of the carrier of a surface-active agent;
- ii) about 2% to about 75% by weight of the carrier of a liquid, non-volatile hydrophobic solvent;
- iii) about 0.01% to about 5% by weight of the carrier of a gelling agent;
- and
- iv) water,
- wherein the ratio of surface active agent to hydrophobic solvent is about 1:8 to about 1:16;
- and
- wherein a breakable foam forms upon dispensing the foamable composition.
Dependencies are inferred from the claim text.